2015

Cynvenio and ATGen Open Recruitment for New LiquidBiopsy Clinical Research Study in Triple Negative Breast Cancer

December 28, 2015 – Cynvenio Biosystems, Inc. and ATGen Global, a Korea-based biotech company, announced the launch of a pilot study to evaluate a new method for early detection of cancer in women who have completed treatment for triple-negative breast cancer (TNBC) and show no radiographic signs of metastases.

Cynvenio Biosystems Announces Collaboration with University of Southern Denmark for Cancer Clinical Trials

December 2, 2015 – Cynvenio announces that it has entered into a strategic collaboration with the Institute of Regional Health Research for the Region of Southern Denmark at the University of Southern Denmark to conduct a wide array of clinical cancer trials using Cynvenio’s Triple Play LiquidBiopsy® platform.

Cynvenio Biosystems and ATGen Announce Strategic Partnership to bring NK Vue Natural Killer Cell Test to US Market

September 29, 2015 – Cynvenio Biosystems, Inc. and ATGen Global, a private biotech company in Korea that manufactures and supplies a wide array of recombinant proteins and antibodies worldwide, announces the companies a collaborative partnership to bring ATGen’s NK Vue™ test to the US market.

Cynvenio Biosystems Announces $25.5 million Series B Financing

June 15, 2015 – Cynvenio Biosystems, Inc. announces the completion a $25.5 million Series B equity financing. Proceeds from the investment will be used to advance the company’s clinical development and commercialization programs. The Series B round was led by Livzon Pharmaceutical Group, Inc. a diversified drug, diagnostics and healthcare company based in Zhuhai, P.R. China. Other investors included Greenwoods Private Equity Funds (Shanghai) and Syno Capital (New York), among others.

Cynvenio to present new clinical data on concordance characteristics of circulating cell-free nucleic acids in metastatic cancer mutations at Molecular Diagnostics Europe

April 13, 2015 – Cynvenio Biosystems, Inc. to present recent findings that establish that both CTC DNA and cfDNA can be used as informative and complementary data types for the analysis of tumor-associated mutations by next generation sequencing (NGS) at next month’s third international Molecular Diagnostics Europe event in Lisbon, Portugal. 

GenomeWeb: Companies Increasingly Aim to Tap into Growing Liquid Biopsy Market

Jan. 26, 2015 - With evidence building that monitoring a tumor's mutational landscape can be done by evaluating circulating tumor DNA or circulating tumor cells, companies are increasingly looking to move into the liquid biopsy market. Over the last month, the larger players in cancer genomics have all announced their intentions to get into the market, as well.  

Thermo Fisher Scientific Signs Distribution Agreement with Cynvenio for LiquidBiopsy Platform

January 13, 2015 - Thermo Fisher Scientific announces it has signed an agreement with Cynvenio for rights to distribute its LiquidBiopsy platform. The addition of Cynvenio’s rare cell enrichment technology complements Thermo Fisher’s Ion Torrent Personal Genome Machine (PGM) workflow and positions the company as the only one in the industry to offer a comprehensive sample-to-genomic data solution for research using a single blood draw for analysis of circulating tumor cells (CTC), cell-free DNA (cfDNA) and normal DNA in less than 48 hours.

Cynvenio Biosystems Shipping First Complete Genomic Testing Solution for Liquid Biopsies in Oncology

January 02, 2015 – Cynvenio announces nationwide availability of its LiquidBiopsy® platform, which utilizes a blood sample to perform sequence analysis and genomic reporting. This platform gives doctors and cancer researchers the ability to perform next-generation sequencing (NGS) on rare populations of circulating tumor cells and cell-free DNA from whole blood.